Incyte INCY · NASDAQ
$113.07 -0.18% (-$0.20)
Summary
89 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 62% a year over the last 3 years.
- Out of every 100 USD of revenue, 28 USD is left as net profit.
- It earns 23 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $3.98B against $38.3M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 14.2 USD for 1 USD of yearly profit. Over the last five years it was 111.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 15%. Earnings per share grew by 62% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 7.4 USD
- Research and development 37 USD
- Sales and administration 24 USD
- Taxes and other 3.9 USD
- Net profit 28 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 28 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 23
- Hold 20
- Sell 1
Today's price within the analysts' price targets
The average target of $132.07 is 17% above today's price. 52% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- J A K A F I 71%
- OPZELURA 14%
- Milestone And Contract Revenue 3.0%
- Olumiant Royalty 2.9%
- M I N J U V I 2.9%
- Other 6.3%
By region
- U [S] 94%
- Europe 6.3%
J A K A F I brings in 71% of revenue. OPZELURA grew fastest, by 243% a year.
Segments in detail